Otsuka Subsidiary Colon Cancer Drug Meets Phase II Endpoint
This article was originally published in PharmAsia News
Executive Summary
Tokyo-based Otsuka Holdings pharmaceutical subsidiary Taiho Pharmaceutical announced the results of a Phase II clinical trial for TAS-102 for metastatic colorectal cancer